Charles Anderson, MD
Gynecologic Oncology · Eugene, ORNPI 1215191259
Payments from drug & device makers
Across 1,148 payments — averaging $5229.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2.4M
- Merck$1.5M
- Tesaro, Inc.$843K
- Pfizer$438K
- Genentech, Inc.$404K
- Genmab U.S., Inc.$138K
- plus $320K from 15 others
Across 8 payments — averaging $334.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 124 | $2,376,320 |
| Merck | 663 | $1,483,704 |
| Tesaro, Inc. | 34 | $843,230 |
| Pfizer | 71 | $438,103 |
| Genentech, Inc. | 13 | $404,306 |
| Genmab U.S., Inc. | 3 | $138,256 |
| Alkermes, Inc. | 8 | $136,806 |
| Karyopharm Therapeutics Inc. | 34 | $73,236 |
| AstraZeneca | 11 | $58,507 |
| Intuitive Surgical | 54 | $14,268 |
| Astrazeneca UK Limited | 6 | $12,405 |
| Acerta Pharma LLC | 1 | $10,125 |
| Corcept Therapeutics | 6 | $5,231 |
| AbbVie | 5 | $3,135 |
| Incyte Corporation | 105 | $2,870 |
| Seagen Inc. | 2 | $2,496 |
| Foundation Medicine, Inc. | 2 | $130 |
| Gen-probe Sales & Service, Inc. | 1 | $122 |
| Baxter Healthcare | 3 | $109 |
| Myriad Genetic Laboratories, Inc. | 1 | $80 |
| Astellas Pharma US Inc | 1 | $28 |
How this compares
$6,003,465 in reported general payments places this provider in the 95th percentile of 25 gynecologic oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gynecologic oncology in Eugene
- Audrey GarrettEugene$596K
- Jennifer GordonEugene$4K
- Kathleen YangEugene$1K
- Christopher DarusPortland$2.7M
- Erin SalinasPortland$1.4M
- Gina WesthoffPortland$960K
- William WinterTigard$957K
- Lisa McCluskeyPortland$142K
- Elizabeth MunroPortland$82K
- Koenraad de GeestPortland$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.